The number of healthcare firms that have gone public on the U.S. stock exchanges so far this month is 17.
Let's take a look at the IPOs scheduled for Friday (Oct 30).
In the healthcare sector, 17 companies have made their debut on the NASDAQ so far this month.
Let's take a look at the U.S. healthcare IPOs scheduled for the week.
Foghorn Therapeutics, founded in 2015, is a pre-clinical stage biotechnology company developing drugs that target the *chromatin regulatory system for a wide range of cancers through its proprietary Gene Traffic Control Product Platform. *The chromatin regulatory system is a system that orchestrates the movement of molecules that turn genes "on" and "off."
Shares of Calliditas Therapeutics AB (CALT) have gained nearly 21% so far this month, as the company gears up for a clinical trial catalyst this quarter.
The number of healthcare firms that have gone public on the U.S. stock exchanges so far this month is 9.
Let's take a look at the IPOs scheduled for tomorrow.
There have been 8 IPOs in the healthcare sector so far this month in the U.S. stock market.
Listed below are the healthcare companies that are going public this week.
Shares of Personalis Inc. (PSNL) closed at an all-time high of $30.52 on Friday (Oct.9, 2020) and that reflects a gain of over 140 percent in 3.5 months after our stock alert.
We are just days into the final quarter of the year. The number of healthcare firms that have gone public on the U.S. stock exchanges so far this month is 4.
Let's take alook at the IPOs scheduled for Friday (Oct 9).
Silver Spring, Maryland-based Aziyo Biologics is scheduled to go public on the Nasdaq Global Select Market under the symbol "AZYO" on October 8, 2020.
The IPO activity in the U.S. pharma/biotech sector has had a strong showing so far this year, with 69 listings compared to only 46 during the same period last year. In the third quarter, 34 companies belonging to the healthcare sector were listed on the major stock exchanges in the US.
The end of the third quarter is fast approaching. The third quarter IPO activity in the U.S. pharma/biotech sector has had a strong showing, with 30 listings so far for the period.
Santa Monica-based GoodRx Holdings, which operates a digital platform for consumer healthcare products and services, is scheduled to make its debut on the Nasdaq Global Select Market under the symbol "GDRX" on September 23, 2020.
Dallas, Texas-based Taysha Gene Therapies is scheduled to make its debut on the Nasdaq Global Select Market under the symbol "TSHA" on September 24, 2020.
Taysha Gene Therapies is a patient-centric gene therapy company developing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system.
Shares of Mersana Therapeutics Inc. (MRSN), which closed at an all-time high of $25.70 yesterday, have gained an impressive 340 percent year-to-date, thanks to positive developments related to its clinical programs.
In the healthcare sector, two companies made their stock market debut in the first half of this month.